Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Immunisation

Opsonophagocytic activity against Streptococcus pneumoniae type 19F in allogeneic BMT recipients before and after vaccination with pneumococcal polysaccharide vaccine

Bone Marrow Transplantation volume 27, pages 207–211 (2001)Cite this article

Abstract

Opsonophagocytic activity (OPA) of pneumococcal polysaccharide (Pnc PS) antibodies in vitro, a measure of antibody functional activity, usually correlates with specific IgG antibody concentrations measured by an EIA method. In order to investigate the functional activity of specific Pnc PS antibodies, we determined IgG antibodies to Pnc PS type 19F by an EIA method and OPA against Pnc type 19F by a killing assay in a randomized study, where 23 adult allogeneic BMT recipients were vaccinated with Pnc PS vaccine at 8 months (early group) and 21 recipients at 20 months (late group) after transplantation. Serum samples drawn before BMT, before vaccination, and at 1 and 16 months after vaccination were available from 27, 35, 34 and 30 patients, respectively. The geometric mean anti-Pnc 19F concentrations were 4.3, 1.3, 1.6 and 1.3 μg/ml in the early group and 3.8, 0.9, 0.6 and 0.6 μg/ml in the late group before transplantation, before vaccination, and at 1 and 16 months after vaccination, respectively. OPA (titre ⩾8) was found in 10/27, 5/35, 5/34 and 6/30 patients before BMT, before vaccination, and at 1 and 16 months after vaccination, respectively. The specific IgG antibody concentration and OPA correlated with each other before BMT, and in the early group patients before and at 1 month after vaccination. The results demonstrate that after Pnc PS vaccination allogeneic BMT recipients have antibodies with low functional activity to a Pnc PS antigen associated with low specific IgG responses. There is a need to study new Pnc conjugate vaccines in multi-dose schedules for their capacity to elicit higher specific antibody concentrations with high OPA in BMT recipients. Bone Marrow Transplantation (2001) 27, 207–211.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Atkinson K, Storb R, Prentice RL et al. Analysis of late infections in 89 long-term survivors of bone marrow transplantation Blood 1979 53: 720–731

    CAS  PubMed  Google Scholar 

  2. Winston DJ, Schiffman G, Wang DC et al. Pneumococcal infections after human bone-marrow transplantation Ann Intern Med 1979 91: 835–841

    Article  CAS  Google Scholar 

  3. Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA . Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation Blood 1990 75: 1583–1586

    CAS  PubMed  Google Scholar 

  4. Wingard JR . Advances in the management of infectious complications after bone marrow transplantation Bone Marrow Transplant 1990 6: 371–383

    CAS  Google Scholar 

  5. Hoyle C, Goldman JM on behalf of 18 UK Bone Marrow Transplant Teams . Life- threatening infections occurring more than 3 months after BMT Bone Marrow Transplant 1994 14: 247–252

    CAS  PubMed  Google Scholar 

  6. Rege K, Mehta J, Treleaven J et al. Fatal pneumococcal infections following allogeneic bone marrow transplant Bone Marrow Transplant 1994 14: 903–906

    CAS  Google Scholar 

  7. Lossos IS, Breuer R, Or R et al. Bacterial pneumonia in recipients of bone marrow transplantation. A five-year prospective study Transplantation 1995 60: 672–678

    Article  CAS  Google Scholar 

  8. Engelhard D, Cordonnier C, Shaw PJ et al. Invasive pneumococcal infection following PBSCT and BMT – an EBMT survey Bone Marrow Transplant 1999 23: (Suppl. 1) S114 (Abstr. 368)

    Google Scholar 

  9. Kulkarni S, Powles R, Treleaven J et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants Blood 2000 95: 3683–3686

    CAS  PubMed  Google Scholar 

  10. Juliá A, Acebedo G, Jornet J, Zuazu J . Spontaneous pneumococcal peritonitis: Late infection after bone-marrow transplantation (letter) New Engl J Med 1985 312: 587

    PubMed  Google Scholar 

  11. Schwella N, Schwerdtfeger R, Schmidt-Wolf I et al. Pneumococcal arthritis after allogeneic bone marrow transplantation Bone Marrow Transplant 1993 12: 165–166

    CAS  PubMed  Google Scholar 

  12. Winston DJ, Ho WG, Schiffman G et al. Pneumococcal vaccination of recipients of bone marrow transplants Arch Intern Med 1983 143: 1735–1737

    Article  CAS  Google Scholar 

  13. Giebink GS, Warkentin PI, Ramsay NKC, Kersey JH . Titers of antibody to pneumococci in allogeneic bone marrow transplant recipients before and after vaccination with pneumococcal vaccine J Infect Dis 1986 154: 590–596

    Article  CAS  Google Scholar 

  14. Barra A, Cordonnier C, Preziosi M-P et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients J Infect Dis 1992 166: 1021–1028

    Article  CAS  Google Scholar 

  15. Lortan JE, Vellodi A, Jurges ES, Hugh-Jones K . Class- and subclass-specific pneumococcal antibody levels and response to immunization after bone marrow transplantation Clin Exp Immunol 1992 88: 512–519

    Article  CAS  Google Scholar 

  16. Hammarström V, Pauksen K, Azinge J et al. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction Support Care Cancer 1993 1: 195–199

    Article  Google Scholar 

  17. Guinan EC, Molrine DC, Antin JH et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients Transplantation 1994 57: 677–684

    Article  CAS  Google Scholar 

  18. Molrine DC, Guinan EC, Antin JH et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation Blood 1996 87: 3012–3018

    CAS  Google Scholar 

  19. Kalhs P, Panzer S, Kletter K et al. Functional asplenia after bone marrow transplantation. A late complication related to extensive chronic graft-versus-host disease Ann Intern Med 1988 109: 461–464

    Article  CAS  Google Scholar 

  20. Picardi M, Selleri C, Rotoli B . Spleen sizing by ultrasound scan and risk of pneumococcal infection in patients with chronic GVHD: preliminary observations Bone Marrow Transplant 1999 24: 173–177

    Article  CAS  Google Scholar 

  21. Brown EJ, Hosea SW, Hammer CH et al. A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia J Clin Invest 1982 69: 85–98

    Article  CAS  Google Scholar 

  22. Tuomanen EI, Austrian R, Masure HR . Pathogenesis of pneumococcal infection New Engl J Med 1995 332: 1280–1284

    Article  CAS  Google Scholar 

  23. Parkkali T, Käyhty H, Ruutu T et al. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT Bone Marrow Transplant 1996 18: 961–967

    CAS  Google Scholar 

  24. Käyhty H, Åhman H, Rönnberg PR et al. Pneumococcal polysaccharide- meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children J Infect Dis 1995 172: 1273–1278

    Article  Google Scholar 

  25. Quataert SA, Kirch CS, Wiedl LJ et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S Clin Diagn Lab Immunol 1995 2: 590–597

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Anttila M, Voutilainen M, Jäntti V et al. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae Clin Exp Immunol 1999 118: 402–407

    Article  CAS  Google Scholar 

  27. Kaniuk AStC, Lortan JE, Monteil MA . Specific IgG subclass antibody levels and phagocytosis of serotype 14 pneumococcus following immunization Scand J Immunol 1992 36: (Suppl. 11) 96–98

    Article  Google Scholar 

  28. Lortan JE, Kaniuk AStC, Monteil MA . Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults Clin Exp Immunol 1993 91: 54–57

    Article  CAS  Google Scholar 

  29. Goughlin RT, White AC, Anderson CA et al. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults Vaccine 1998 16: 1761–1767

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Haematology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland

    T Parkkali & T Ruutu

  2. National Public Health Institute, Helsinki, Finland

    M Văkevăinen, H Kăyhty & P Ruutu

Authors
  1. T Parkkali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Văkevăinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Kăyhty
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Ruutu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Ruutu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parkkali, T., Văkevăinen, M., Kăyhty, H. et al. Opsonophagocytic activity against Streptococcus pneumoniae type 19F in allogeneic BMT recipients before and after vaccination with pneumococcal polysaccharide vaccine. Bone Marrow Transplant 27, 207–211 (2001). https://doi.org/10.1038/sj.bmt.1702779

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702779

Keywords

This article is cited by

Search

Advanced search

Quick links